PT-141
Refilling Soon
This peptide is currently out of stock. Get notified the moment it's available.
About PT-141
PT-141 (Bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist with selective activity primarily at MC3R and MC4R, derived from Melanotan II. Unlike PDE5 inhibitors that work through vascular mechanisms, PT-141 acts centrally via melanocortin pathways in the hypothalamus to modulate sexual motivation and arousal signalling — a fundamentally distinct CNS mechanism. In 2019, PT-141 became the first FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women, under the brand name Vyleesi, providing strong translational validation for its mechanism. Pre-clinical studies across multiple species have demonstrated dose-dependent increases in sexual motivation behaviours through CNS melanocortin pathway activation, independent of peripheral vasodilation. Research applications include sexual dysfunction pharmacology, CNS melanocortin receptor biology, and reward pathway neuroscience. Its FDA-approval history makes PT-141 one of the best-translated research peptides in CNS pharmacology. Supplied at ≥99% HPLC purity.
Usage Guidelines
✓ Suitable For
- Highly validated compound — FDA-approved mechanism provides strong translational research value
- Ideal for CNS melanocortin receptor biology and sexual function pharmacology research
- Selective MC3R/MC4R profile reduces off-target effects vs Melanotan II
- Suitable for reward pathway and arousal neuroscience investigations
✗ Not Recommended For
- Not for use in individuals with cardiovascular conditions without medical clearance
- Monitor blood pressure — transient elevations can occur via melanocortin pathways
- For research and supervised clinical protocols only
- Not intended for recreational or unsupervised use — consult a physician before any protocol